Some of the Best Penny Stocks
Mentioned below are a few of the coming penny stocks.
CELL or Brightpoint
CELL is a company offering device lifecycle services to the high-tech and wireless industries. The services offered by them include inventory management, fulfillment, demand planning, kitting, procurement, software loading, credit services, customized packaging and more. In just a week, shares of CELL are up by a remarkable 65%. There has to be big news! Ingram Micro, the technology distributor is buying CELL. Ingram is shelling out approximately $650 million for the company or about $9 per share. That means a 66% premium on the stock price before the announcement. This explains the jump in shares perfectly. This deal looks like done and this is also a fair indication that there may be other deals on the way. With competition intensifying in the tablet and smarthphone market PC companies could be looking to spreading out into the wireless market.
JMBA or Jamba
JMBA Shares are up by a strong 37% in the last week. Jamba Juice stores and franchises are owned by JMBA. The company is a restaurant retailer of food products and specialty beverages such as smoothies, hot teas, squeezed juices, hot oatmeal as well as other drinks and food products. Let’s look at the deal… Recently JMBA has started a forceful marketing campaign and to popularize their stores are partnering with big sports stars like Venus Williams. Venus is starting her personal store in Washington DC. Their latest marketing strategy with aggressive opening of stores is leaving an effect on investors. Till now they look like supporting the efforts of the company fully and the stock continues to move northwards.
NSPH or Nanosphere
Molecular diagnostics platform is developed by NSPH which allows protein and genomic testing on one single platform. The main product of the company is utilized for testing pharmacogenetic and human assays, ultra-sensitive protein assays as well as infectious disease assays. NSPH shares have seen an increase of about 55% in the last week. What is the reason behind it? Bloodstream infection test developed by NSPH has been approval by the FDA recently. Not just that Jefferies as well as Roth Capital have upgraded this stock with that approval and Roth has set a price target of $4.50. During the time of writing the stock was trading at about $3.20, there is more of upside coming. Not surprising that investors are not leaving the chance to get the shares.